Zanubrutinib with chemo for mantle cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of targeted therapy (zanubrutinib) and chemotherapy (bendamustine and rituximab) for people newly diagnosed with mantle cell lymphoma. It is designed for older adults, those with certain genetic changes (TP53), or those who cannot tolerate standard chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have mantle cell lymphoma that was just diagnosed.
- You are 65 years or older, or have a specific genetic change (TP53 alteration), or are under 65 but cannot tolerate chemotherapy.
- Your kidneys are working well enough (based on blood tests).
- Your heart pumps at least half the normal amount (LVEF 50% or higher).
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of medications that include zanubrutinib (a targeted therapy) for people newly diagnosed with mantle cell lymphoma. It aims to see how well these treatments work and if they are safe.
This trial is testing a medicine called zanubrutinib to see if it can help prevent mantle cell lymphoma from coming back after initial treatment. It is for people who have already finished their first treatment and achieved at least a partial response.
This trial is testing a combination of two targeted drugs, orelabrutinib and rituximab, as a first treatment for mantle cell lymphoma (MCL). Some patients may also get a stem cell transplant. The goal is to see how well this approach works.
This trial tests whether adding the targeted drug zanubrutinib to standard chemotherapy (R-CHOP or R-DHAP) helps people with untreated mantle cell lymphoma. It is for adults up to age 70 who are healthy enough for intensive treatment.
This trial tests two targeted drugs, zanubrutinib and tafasitamab, for people with mantle cell lymphoma. The goal is to see if this combination works better than standard treatments.
This trial is testing a combination of chemotherapy and targeted drugs for people who have just been diagnosed with mantle cell lymphoma and haven't had any prior treatment (except short-term steroids or local radiation). It aims to see if adding newer targeted therapies can help keep the lymphoma in remission.
Hear when a new Lymphoma, Mantle-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.